The Colorectal Cancer Resource & Action Network (CCRAN) is excited to announce its third annual Pan-Tumour Biomarkers Conference, scheduled to take place virtually on June 19 - 20, 2025. This event highlights the growing importance of comprehensive genomic profiling (CGP) and biomarker-driven treatments in cancer care, showcasing CCRAN's leadership in Canada's precision medicine movement.

Against the backdrop of provinces and territories aligning clinical innovation with system delivery, this year's conference will bring together healthcare leaders, policymakers, researchers, industry experts, and patient communities to discuss the integration of CGP into cancer care. The agenda will focus on health system readiness, policy development, and advocacy strategies to ensure the widespread adoption of genomic testing, particularly CGP, across Canada's cancer care landscape.

One of the key features of the 2025 Conference is the keynote presentation by the Conference Board of Canada, unveiling a groundbreaking cost-benefit analysis that demonstrates the transformative value of CGP in five tumour types - lung, colorectal, breast, pancreatic, and prostate. This analysis will highlight the significant return on investment in modernizing Canada's testing infrastructure and the benefits to patients, including improved survival rates, enhanced quality of life, reduced treatment toxicity, and quicker access to targeted therapies.

CCRAN's ongoing efforts to promote biomarker-driven cancer care through education, policy dialogue, and partnerships will be further emphasized during the event. The organization aims to advocate for public access to biomarker testing and facilitate discussions on the importance of timely, standardized, and publicly funded diagnostics.

The Conference is open to healthcare professionals, administrators, researchers, policymakers, patients, caregivers, and anyone interested in shaping a more personalized and equitable future for cancer care in Canada. CCRAN acknowledges its premier partners - Merck, AstraZeneca, Roche, Johnson & Johnson - for their commitment to advancing precision medicine in Canada, along with other sponsors and patient advocacy groups.

Registration for the conference is free, and all sessions will be conducted virtually with the option for post-event viewing. To register and access the full agenda, visit the official website at: www.ccran.org/biomarkers-conference

For media inquiries or additional information, please contact [email protected]